JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 3, 2004; DOI: 10.1124/jpet.104.069856


0022-3565/04/3111-394-401$20.00
JPET 311:394-401, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.069856v1
311/1/394    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Godoy, M. A. F.
Right arrow Articles by Rattan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Godoy, M. A. F.
Right arrow Articles by Rattan, S.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Angiotensin II-Induced Relaxation of Anococcygeus Smooth Muscle via Desensitization of AT1 Receptor, and Activation of AT2 Receptor Associated with Nitric-Oxide Synthase Pathway

Márcio A. F. de Godoy, Ana Maria de Oliveira, and Satish Rattan

Department of Medicine, Division of Gastroenterology & Hepatology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania (M.A.F.d.G., S.R.); and Laboratory of Pharmacology, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil (A.M.d.O.)

We evaluated the role of receptor desensitization, activation of AT2 receptors, and enzymatic degradation of angiotensin II (Ang II) by amino/neutral endopeptidases in rat anococcygeus smooth muscle (ASM) relaxation. Ang II (0.3 nM to 10 µM) produced contractions (Emax = 21.50 ± 5.73%) followed by passive relaxations (Emax reduced to 9.08 ± 2.55%). Contractions were inhibited (Emax = 13.67 ± 2.03%) by losartan (0.1 µM; AT1 antagonist) but not by PD123,319 [S-(+)-1-([4-(dimethylamino)-3-methylphenyl]methyl)-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo(4,5-c)pyridine-6-carboxylic acid] (0.1 µM; AT2 antagonist). Conversely, the passive relaxation was inhibited (Emax = 18.00 ± 3.45%) by PD123,319 but not by losartan. Ang II (0.3 µM to 100 µM) produced initial contractions (Emax = 11.49 ± 9.39%) followed by active relaxations [Imax (maximum inhibition elicited by the agonist) = 47.85 ± 4.23%] on strips precontracted by bethanechol (100 µM). A second administration of Ang II on the background of bethanechol (1 h later) resulted in stronger relaxations (Imax = 64.03 ± 5.47%) without the initial contractions. NG-Nitro-L-arginine methyl ester [nitric-oxide synthase (NOS) inhibitor], ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; guanylate cyclase inhibitor), PD123,319, and tetrodotoxin (neurotoxin) inhibited the relaxations. The presence of AT1 and AT2 receptors was confirmed by Western blot. Experiments with amastatin (1 µM) and thiorphan (1 µM), aminopeptidase, and neutral endopeptidase inhibitors, respectively, excluded the involvement of enzymatic degradation in Ang II-induced relaxation of ASM. In conclusion, the rat ASM relaxation by Ang II is the result of active and passive relaxations. The passive relaxation depends on desensitization of excitatory AT1 receptors, and the active relaxation is mediated by stimulation of AT2 receptors and activation of the neuronal NOS/soluble guanylate cyclase pathway.


Received April 12, 2004; accepted June 2, 2004.

Address correspondence to: Dr. Satish Rattan, Jefferson Medical College, Thomas Jefferson University, 1025 Walnut Street, Room # 901 College, Philadelphia, PA 19107. E-mail: satish.rattan{at}jefferson.edu




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
N. Toda, K. Ayajiki, and T. Okamura
Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation
Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. F. de Godoy and S. Rattan
Translocation of AT1- and AT2-Receptors by Higher Concentrations of Angiotensin II in the Smooth Muscle Cells of Rat Internal Anal Sphincter
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1088 - 1095.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. A. F. De Godoy and S. Rattan
Autocrine regulation of internal anal sphincter tone by renin-angiotensin system: comparison with phasic smooth muscle
Am J Physiol Gastrointest Liver Physiol, December 1, 2005; 289(6): G1164 - G1175.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
B. T. Andresen, K. Shome, E. K. Jackson, and G. G. Romero
AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity
Am J Physiol Renal Physiol, April 1, 2005; 288(4): F763 - F770.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.